With COVID-19 cases soaring across the US and worldwide, the need for a vaccine could not be greater. Here’s where we stand on vaccine development, including positive results from Pfizer’s trial.
Rigor académico, oficio periodístico
Artículos sobre Moderna
Mostrando 61 - 66 de 66 artículos
So-called mRNA vaccines are among the frontrunners in the global race to design a COVID vaccine. But as a new technology, most nations, including Australia, lack the capacity to produce them at scale.
Both Moderna and AstraZeneca have used cutting-edge designs to reduce their vaccines’ development time.
The results from the phase 1 trial are a promising first step in showing that the mRNA vaccine is a viable candidate, but there are unanswered questions and it is still early in the process.
Results from phase 1 trials of a COVID-19 mRNA vaccine created a burst of optimism. But details the company failed to release suggest it is too early to speculate whether the vaccine is effective.
Vaccine development is usually a long process. The coronavirus pandemic is forcing researchers to innovate and test potential vaccines faster than ever before.
Principales colaboradores
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Medicine, University of Virginia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Microbiology, School of Medicine, University of Washington
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Joel Lexchin es Amigo de The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Assistant Professor, School of Professional Communication, Toronto Metropolitan University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Law, Villanova School of Law
-
Professorial Fellow, University of Canberra
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Associate Professor of Bioethics, University of Portsmouth
-
Associate Professor of Epidemiology, University of San Francisco
-
Professor of Epidemiology, Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne
